bioRxiv Science⌕ Search

Biology subjects

Blohm, U.

Publications and source records attributed to Blohm, U..

2 recordsLinked to original sources

HERC4 limits oxidative stress-induced DNA damage during bacterial and viral-bacterial infection

Respiratory (co-)infections caused by influenza viruses and Streptococcus pneumoniae represent significant threats to global health. In our analysis of host cell ubiquitination, we identified reactive oxygen species (ROS) produced by S. pneumoniae as critical effectors in reducing the amount of intracellular polyubiquitinated proteins. Together with reduced ubiquitination we observed a downregulation of the E3 ligase HERC4 upon infection with S. pneumoniae in human alveolar epithelial and macrophage-like cells as well as in samples obtained from S. pneumoniae infected humans and mice. This was further aggravated in the viral-bacterial coinfection with influenza A. CRISPR-Cas9 deletion of HERC4 prior bacterial infection resulted in increased ROS-induced DNA damage, enhanced host cell apoptosis and reduced Histone 2B ubiquitination. In contrast, HERC4 overexpression diminished DNA damage indicating a role of HERC4 in DNA-damage-repair upon infection. By establishing a link between HERC4 expression and ROS-induced DNA damage and repair, we identified a potential marker for predicting the outcome of viral and bacterial (co-)infections. Targeting HERC4 expression defines a novel strategy to protect host cells from S. pneumoniae (co-)infection attenuating infection exacerbation.

microbiology↗

A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae

Streptococcus pneumoniae infections are the leading cause of child mortality globally. Current vaccines fail to induce a protective immune response towards a conserved part of the pathogen, resulting in new serotypes causing disease. Therefore, new vaccine strategies are urgently needed. Described is a two-pronged approach combining S.pneumoniae proteins, pneumolysin and PspA, with a precisely defined synthetic oligosaccharide, whereby the carrier protein acts as a serotype-independent antigen to provide additional protection. Proof of concept in mice and swine models revealed that the conjugates inhibit colonization of the nasopharynx, decrease the bacterial load and reduce disease severity in the bacteria challenged model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model. A combination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective ("universal") pneumococcal vaccines.

immunology↗